Ann: IMU Meets Endpoints in Phase 1b Gastric Cancer Trial, page-85

Super, you said, 

'So I guess some of those four pulled out early and others were late arrivals. happens a lot in trials like this with severely ill patients, that they pull out early.'

After 'late arrivals', I would have added 'or died'.  One way to avoid guessing is for the company to be EXPLICIT when announcing such simple facts. Then nobody is confused or makes erroneous assumptions. Not giving much away by clearly stating numbers. We don't even know how many were in each dosage cohort, how many pulled out or died or how many additional patients were enrolled after the last 'official' trial recruitment (as per recruitment end ann) and whether any of these were included in the 'evaluable' 10 patients. IMO, such info should be clearly given in top line results. It is not rocket science to quote numbers.

After saying the above, the top line P1 data revealed thus far, IMO, makes IMU a stand out risk vs potential reward gamble ( ...err, investment). Hopefully the market will start to form the same opinion and free the SP from the shackles of the money game constraints.